Regulatory Guidance Monthly Review - Sept 2021

September 2021 


Veristat_Blog_Regulatory September 2021

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.   Below are the relevant links to updates provided for both COVID-19 related and non-COVID-19 related programs in August 2021.

 

Blog Image-Regulatory Guidanc eMonthly_FDAupdates-1

 

New FDA Guidance Documents:

 

Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations:  Guidance for Industry (published 29-Sep-2021)

Download FDA Guidance

 

Questions and Answers on Quality-Related Controlled Correspondence Guidance for Industry:  Guidance for Industry (published 20-Sep-2021)

Download FDA Guidance

 

Q2(R1) Validation of Analytical Procedures: Text and Methodology  Guidance for Industry:  Guidance for Industry (published 16-Sep-2021)

Download FDA Guidance

 

Development of Abbreviated New  Drug Applications During the  COVID-19 Pandemic – Questions and  Answers Guidance for Industry:  COVID 19 Guidance (published 08-Sep-2021)

Download FDA Guidance

 

New Draft Guidance Documents:

 

Benefit-Risk Assessment for New Drug and Biological Products (published 29-Sep-2021)

Download Draft FDA Guidance

 

Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial: Draft Guidance for Industry (published 29-Sep-2021)

Download Draft FDA Guidance

 

Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium avium Complex:  Developing Drugs for Treatment: Draft Guidance for Industry (published 28-Sep-2021)

Download Draft FDA Guidance

 

Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products: Draft Guidance for Industry (published 28-Sep-2021)

Download Draft FDA Guidance


 

Blog Image-Regulatory Guidanc eMonthly_Regulatory Agencies in the News

 

FDA revises MAPPs on data standards program, scientific interest groups (published 01-Sep-2021)
Read Article on RAPS.org

 

FDA proposes to refuse Intarcia’s exenatide combo product NDA —again (published 01-Sep-2021)
Read Article on RAPS.org

 

FDA convenes adcomm for Pfizer COVID booster (published 01-Sep-2021)
Read Article on RAPS.org

 

Top FDA and EMA officials to kick-off Convergence 2021 (published 02-Sep-2021)
Read Article on RAPS.org

 

JAK inhibitors' CV, cancer risks merit expanded boxed warning (published 02-Sep-2021)
Read Article on RAPS.org

 

Animal models have limitations for safety assessment of gene therapies: FDA adcomm (published 02-Sep-2021)
Read Article on RAPS.org

 

Analyses reveal wide variation in PRO measures in cancer trials (published 07-Sep-2021)
Read Article on RAPS.org

 

FDA extends comment period on ICH Q12 guidance (published 08-Sep-2021)
Read Article on RAPS.org

 

EU committee considers antimicrobial incentives, repurposing oncology drugs (published 08-Sep-2021)
Read Article on RAPS.org

 

FDA’s novel excipient pilot program opens for candidates (published 08-Sep-2021)
Read Article on RAPS.org

 

US to continue international inspection cooperation, says Marks (published 09-Sep-2021)
Read Article on RAPS.org

 

FDA updates guidance on generic drug development during COVID (published 09-Sep-2021)
Read Article on RAPS.org

 

Kaleido warned; FDA not persuaded by 'medical food' claim (published 09-Sep-2021)
Read Article on RAPS.org

 

HMA-EMA plans real-world metadata framework for regulatory decision-making (published 10-Sep-2021)
Read Article on RAPS.org

 

Industry calls for withdrawal of FDA electronic tracing guidance (published 10-Sep-2021)
Read Article on RAPS.org

 

Convergence: Regulatory considerations in advancing gene and cellular therapies (published 13-Sep-2021)
Read Article on RAPS.org

 

Convergence: EMA study reveals need for RWE framework, submission structure (published 14-Sep-2021)
Read Article on RAPS.org

 

Tips for avoiding regulatory pitfalls in pediatric drug development (published 14-Sep-2021)
Read Article on RAPS.org

 

Global regulatory workforce nearly 100K, says new report from RAPS, Elemed (published 15-Sep-2021)
Read Article on RAPS.org

 

Convergence: Inadequate testing of cell and gene therapies draws FDA concern (published 15-Sep-2021)
Read Article on RAPS.org

 

FDA, EMA launch complex generic, hybrid product advice pilot (published 15-Sep-2021)
Read Article on RAPS.org

 

FDA continues data modernization with new Office of Digital Transformation (published 16-Sep-2021)
Read Article on RAPS.org

 

FDA guidance covers frequently asked CMC questions for generic drugs (published 21-Sep-2021)
Read Article on RAPS.org

 

Review highlights lack of consistency in FDA’s ‘close call’ approvals (published 23-Sep-2021)
Read Article on RAPS.org

 

WHO seeks input on medicines to prioritize for BCS-based biowaivers (published 27-Sep-2021)
Read Article on RAPS.org

 

Drugs for non-TB pulmonary disease see new FDA guidance (published 28-Sep-2021)
Read Article on RAPS.org

 

FDA issues draft guidance on electronic 510(k) submissions (published 28-Sep-2021)
Read Article on RAPS.org

 

FDA issues draft guidance on RWD sourced from EHRs, claims data (published 29-Sep-2021)
Read Article on RAPS.org

 

For gene therapies, FDA drafts trial guidance, finalizes "sameness" for orphan exclusivity (published 30-Sep-2021)
Read Article on RAPS.org

 


 

Explore-More-Image-1